OBJECTIVES: The aim of this paper was to examine disparities in the use of cardioprotective medications in the treatment of peripheral artery disease (PAD) by socioeconomic status (SES). BACKGROUND: PAD is associated with increased cardiovascular risk and is more prevalent among those of lower SES. However, the use of guideline-recommended secondary preventive measures for the treatment of PAD across diverse income subgroups and the influence of practice site on potential treatment disparities by SES are unknown. METHODS: Within the National Cardiovascular Disease Registry (NCDR) PINNACLE Registry, 62,690 patients with PAD were categorized into quintiles of SES, as defined by the median income of each patient's zip code. The association between SES and secondary preventive treatment with antiplatelet and statin medications was evaluated using sequential hierarchical modified Poison models, adjusting first for practice site and then for clinical variables. RESULTS: Compared with the highest SES quintile (median income: >$60,868), PAD patients in the lowest SES quintile (median income: <$34,486) were treated less often with statins (72.5% vs. 85.8%; RR: 0.84; 95% CI: 0.83 to 0.86; p < 0.001) and antiplatelet therapy (79.0% vs. 84.6%; RR: 0.93; 95% CI: 0.91 to 0.94; p < 0.001). These differences were markedly attenuated after controlling for practice site variation: statins (adjusted RR: 0.97; 95% CI: 0.95 to 0.99; p = 0.003) and antiplatelet therapy (adjusted RR: 0.98; 95% CI: 0.97 to 1.00; p = 0.012). Additional adjustment for patients' clinical characteristics had minimal impact, with slight further attenuation with statins (adjusted RR: 1.00: 95% CI: 0.99 to 1.01; p = 0.772) and antiplatelet therapy (adjusted RR: 1.00; 95% CI: 0.99 to 1.01; p = 0.878). CONCLUSIONS: Among PAD patients, the practice site at which patients received care largely explained the observed SES differences in treatment with guideline-recommended secondary preventive medications. Future efforts to reduce treatment disparities in these vulnerable populations should target systems improvement at practices serving high proportions of patients with low SES.
OBJECTIVES: The aim of this paper was to examine disparities in the use of cardioprotective medications in the treatment of peripheral artery disease (PAD) by socioeconomic status (SES). BACKGROUND: PAD is associated with increased cardiovascular risk and is more prevalent among those of lower SES. However, the use of guideline-recommended secondary preventive measures for the treatment of PAD across diverse income subgroups and the influence of practice site on potential treatment disparities by SES are unknown. METHODS: Within the National Cardiovascular Disease Registry (NCDR) PINNACLE Registry, 62,690 patients with PAD were categorized into quintiles of SES, as defined by the median income of each patient's zip code. The association between SES and secondary preventive treatment with antiplatelet and statin medications was evaluated using sequential hierarchical modified Poison models, adjusting first for practice site and then for clinical variables. RESULTS: Compared with the highest SES quintile (median income: >$60,868), PAD patients in the lowest SES quintile (median income: <$34,486) were treated less often with statins (72.5% vs. 85.8%; RR: 0.84; 95% CI: 0.83 to 0.86; p < 0.001) and antiplatelet therapy (79.0% vs. 84.6%; RR: 0.93; 95% CI: 0.91 to 0.94; p < 0.001). These differences were markedly attenuated after controlling for practice site variation: statins (adjusted RR: 0.97; 95% CI: 0.95 to 0.99; p = 0.003) and antiplatelet therapy (adjusted RR: 0.98; 95% CI: 0.97 to 1.00; p = 0.012). Additional adjustment for patients' clinical characteristics had minimal impact, with slight further attenuation with statins (adjusted RR: 1.00: 95% CI: 0.99 to 1.01; p = 0.772) and antiplatelet therapy (adjusted RR: 1.00; 95% CI: 0.99 to 1.01; p = 0.878). CONCLUSIONS: Among PAD patients, the practice site at which patients received care largely explained the observed SES differences in treatment with guideline-recommended secondary preventive medications. Future efforts to reduce treatment disparities in these vulnerable populations should target systems improvement at practices serving high proportions of patients with low SES.
Authors: Jeffrey W Olin; David E Allie; Michael Belkin; Robert O Bonow; Donald E Casey; Mark A Creager; Thomas C Gerber; Alan T Hirsch; Michael R Jaff; John A Kaufman; Curtis A Lewis; Edward T Martin; Louis G Martin; Peter Sheehan; Kerry J Stewart; Diane Treat-Jacobson; Christopher J White; Zhi-Jie Zheng Journal: J Vasc Surg Date: 2010-12 Impact factor: 4.268
Authors: Telly A Meadows; Deepak L Bhatt; Alan T Hirsch; Mark A Creager; Robert M Califf; E Magnus Ohman; Christopher P Cannon; Kim A Eagle; Mark J Alberts; Shinya Goto; Sidney C Smith; Peter W F Wilson; Karol E Watson; P Gabriel Steg Journal: Am Heart J Date: 2009-12 Impact factor: 4.749
Authors: Paul S Chan; William J Oetgen; Donna Buchanan; Kristi Mitchell; Fran F Fiocchi; Fengming Tang; Philip G Jones; Tracie Breeding; Duane Thrutchley; John S Rumsfeld; John A Spertus Journal: J Am Coll Cardiol Date: 2010-06-29 Impact factor: 24.094
Authors: Colleen G Koch; Liang Li; George A Kaplan; Jared Wachterman; Mehdi H Shishehbor; Joseph Sabik; Eugene H Blackstone Journal: Circ Cardiovasc Qual Outcomes Date: 2010-04-06
Authors: Michael H Criqui; John K Ninomiya; Deborah L Wingard; Ming Ji; Arnost Fronek Journal: J Am Coll Cardiol Date: 2008-11-18 Impact factor: 24.094
Authors: Thom W Rooke; Alan T Hirsch; Sanjay Misra; Anton N Sidawy; Joshua A Beckman; Laura K Findeiss; Jafar Golzarian; Heather L Gornik; Jonathan L Halperin; Michael R Jaff; Gregory L Moneta; Jeffrey W Olin; James C Stanley; Christopher J White; John V White; R Eugene Zierler Journal: J Vasc Surg Date: 2011-09-29 Impact factor: 4.268
Authors: Andrew M Davis; Michael S Taitel; Jenny Jiang; Dima M Qato; Monica E Peek; Chia-Hung Chou; Elbert S Huang Journal: J Racial Ethn Health Disparities Date: 2016-06-28
Authors: Ambarish Pandey; Harsh Golwala; Hurst M Hall; Tracy Y Wang; Di Lu; Ying Xian; Karen Chiswell; Karen E Joynt; Abhinav Goyal; Sandeep R Das; Dharam Kumbhani; Howard Julien; Gregg C Fonarow; James A de Lemos Journal: JAMA Cardiol Date: 2017-07-01 Impact factor: 14.676
Authors: Matthew L Topel; Jeong Hwan Kim; Mahasin S Mujahid; Samaah M Sullivan; Yi-An Ko; Viola Vaccarino; Arshed A Quyyumi; Tené T Lewis Journal: Am J Cardiol Date: 2018-10-22 Impact factor: 2.778
Authors: Adelaide M Arruda-Olson; Naveed Afzal; Vishnu Priya Mallipeddi; Ahmad Said; Homam Moussa Pacha; Sungrim Moon; Alisha P Chaudhry; Christopher G Scott; Kent R Bailey; Thom W Rooke; Paul W Wennberg; Vinod C Kaggal; Gustavo S Oderich; Iftikhar J Kullo; Rick A Nishimura; Rajeev Chaudhry; Hongfang Liu Journal: J Am Heart Assoc Date: 2018-12-04 Impact factor: 5.501
Authors: Joseph A Ladapo; Adrian Coles; Rowena J Dolor; Daniel B Mark; Lawton Cooper; Kerry L Lee; Jonathan Goldberg; Michael D Shapiro; Udo Hoffmann; Pamela S Douglas Journal: BMJ Open Date: 2017-09-29 Impact factor: 2.692